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Neurobiology of Fibromyalgia Syndrome
In our review, the neurobiology of fibromyalgia syn-
drome (FM) is discussed in the context of what is known
about neural mechanisms of nociception and central
mechanisms of persistent pain conditions. We present a
general view of mechanisms of nociception, central tem-
poral summation, and central sensitization, and as well
compare sensory tests that examine these mechanisms in
normal pain-free human subjects. We then show how
amplification and other alterations of these mechanisms
apply to patients with FM.
NOCICEPTION, ACUTE PAIN, PERSISTENT PAIN 
Pain is usually related to impulse input that originates
from nociceptors in somatic or visceral tissues. The
impulses travel in myelinated (A-delta) and unmyelinated
(C) peripheral nerves, which first project to dorsal horn
nociceptor-specific neurons and wide dynamic range neu-
rons, before these second-order neurons transmit noci-
ceptive information to brain regions involved in pain,
including the thalamus, anterior cingulate cortex (ACC),
anterior insular cortex, and somatosensory cortex.
Nociceptor-specific neurons are so termed because they
respond predominantly to specific stimulus intensities
that either cause tissue damage or would cause tissue
damage if maintained over time. Wide dynamic range
neurons respond differentially over a very broad range of
stimulus intensities, from very gentle touch to stimuli that
cause tissue damage. Brain regions that receive input
from nociceptor-specific and wide dynamic range neu-
rons are related to sensory-discriminative, cognitive-eval-
uative, and affective processing of somatosensory noci-
ceptive input. The activation of these brain regions is
associated with pain experience and subsequent reflex
and protective behaviors. Importantly, the same brain
areas are likely to be involved in both acute and persist-
ent pain conditions.
Reflex and reflective behaviors that are aimed at elimi-
nating acute pain are not operative in chronic pain syn-
dromes including FM. Patients with FM, like most
chronic pain sufferers, do not display pain behaviors usu-
ally seen in acute pain, including increased perspiration,
hypertension, hyperthermia, and tachycardia. FM
patients have abnormal pain thresholds (hyperalgesia)
and report amplified pain with a variety of nociceptive
stimuli, including pressure, heat, and cold. Because no
consistent tissue abnormalities have been detected in FM,
central pain processing abnormalities need to be consid-
ered as important contributors to the heightened pain
sensitivity of these patients.
In our review, we also discuss recent evidence that the
clinical pain of patients with FM is related to abnormal
central temporal summation of pain, or “windup,”
evoked by repetitive stimulation of peripheral nociceptive
afferent neurons. Sensory testing experiments can be used
to demonstrate that abnormal windup of FM patients is
related to central nervous system (CNS) mechanisms of
central sensitization and persistent pain.
As background to the central sensory abnormalities of
FM patients, we discuss the normal role of nociceptors
and the central consequences of repetitive stimulation of
nociceptive neurons, and also describe how these mecha-
nisms appear to be distorted in FM patients.
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tion. Future research needs to address the important role of abnormal nociception and/or antinociception
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tinguished from second pain by most subjects. In contrast,
second pain (transmitted by unmyelinated C-fibers),
which is thought to be related to some chronic pain states,
is most frequently reported as dull, aching, or burn-
ing8,9,15-17. Similar to windup in the dorsal horn, second
pain increases in intensity when painful stimuli are applied
more often than once every 3 seconds. Windup of both
dorsal horn neurons and second pain can be inhibited by
application of NMDA receptor antagonists, including
dextromethorphan13 and ketamine14. These parallels
between windup of dorsal horn neurons and second pain
almost certainly relate to the fact that dorsal horn neurons
that display windup project to pain-related areas of the
brain via several pathways. These pathways include not
only the well characterized spinothalamic tract, but also
the spinoreticular, spinohypothalamic, and the spinopon-
toamygdaloid pathways18. As a consequence of these mul-
tiple central projections, windup in the dorsal horn is like-
ly to be a major cause of windup of second pain. This is
critical, because windup is likely to be related to mecha-
nisms of central sensitization and hence some persistent
pain conditions19,20.
Several types of well controlled experimental stimuli can
reliably evoke windup of pain when applied to somatic tis-
sues of normal pain-free human subjects8,21,22, including
electrical stimulation of C nociceptors8, thermal stimula-
tion of C nociceptors17, and mechanical stimulation of
muscle nociceptors17,21-24. Figure 1 illustrates the charac-
teristics of windup of second pain evoked in normal pain-
free subjects by repeated thermal stimuli at 52°C.
Some persistent pain conditions including FM are
thought to be related to central mechanisms of sensitiza-
ROLE OF DIFFERENT NOCICEPTORS FOR PAIN
Nociception is associated with activation of a heteroge-
neous group of nociceptors that either express the neu-
ropeptide substance P (SP) and calcitonin gene related
peptide (CGRP) or isolectin B4 (IB4)
1. Their sensory neu-
rons terminate in the dorsal horn of the spinal cord,
mainly in laminae I and II and to a lesser degree in lami-
na V. These spinal cord regions also contain postsynaptic
neurons that express receptors implicated in nociceptive
transmission, such as SP, neurokinin 1, and neurokinin 2,
as well as glutaminergic receptors [N-methyl-D-aspartate
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA), kainate, metabotropic].
TRPV-1 and TRPVL-1 receptors have been recently found
to be activated by noxious heat2, mechanical stimuli, or
low pH (acid-sensing ion channels)3,4. Although IB4-posi-
tive neurons can express several of these receptors, they are
the only ones to display the purino-receptor P2X35. This
latter receptor is activated by purines such as adenosine
triphosphate, which are frequently released after tissue
injury. Very little is known about the receptor expression of
neurons that innervate different tissues of the body, but
some tissues seem to contain special pain receptors. Much
information has been obtained from animal models in
which specific pain receptors are lacking. Inbred mice
without TRPV-1 receptors show decreased response to
noxious heat, but mechanical nociception is normal6.
Alternatively, mice without P2X3 receptors show no
reduced nociceptive behavior using known stimuli.
MECHANISMS OF SLOW TEMPORAL SUMMATION
AND CENTRAL SENSITIZATION
Using electrical shocks to a cutaneous nerve of cats,
Mendell and Wall found that repeated volleys of action
potentials in C-fibers resulted in a progressive increase in
the number of action potentials evoked in second-order
dorsal horn neurons7. Thus, with each successive C-fiber
volley, the evoked impulse discharge of second-order neu-
rons had a higher frequency and was more prolonged.
This progressive increase in response reflects slow tempo-
ral summation and has been termed windup. Windup has
been demonstrated to result from central rather than
peripheral nervous system mechanisms, mostly because
the input from peripheral nociceptors has been shown to
decline or stay the same with stimulus repetition8,9.
Windup of dorsal horn nociceptive neurons involving
NMDA receptor mechanisms10-12 can be attenuated in a
dose-dependent manner by NMDA receptor antago-
nists11-14.
This important mechanism of pain amplification,
which operates at least partly in the dorsal horn of the
spinal cord, precisely parallels the psychophysical charac-
teristics of temporal summation of second pain. First
pain, which is conducted by myelinated A-delta pain
fibers, is often described as sharp and can be readily dis-
Figure 1. Windup of second pain in healthy control subjects. Twenty
repetitive heat stimuli (52°C) were applied to the hand. Contact time
was 0.7 s; interstimulatory intervals (ISI) varied between 3 s and 6 s, as
shown at upper left. Pain intensity of test stimuli was rated on a verbal
rating scale of 0–100 (0 = no pain; 20 = minimal pain; 100 = unbearable
pain). Only repetitive stimuli at short ISI (3 s) resulted in a significant
increase of pain ratings, compared to long ISI, which produced minimal
pain sensations. From Vierck, et al. J Neurophysiol 1997;78:992- 100217.
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ABNORMAL WINDUP IN PATIENTS WITH FM
The noninvasive method of summation of second pain or
windup has been used for the evaluation of central pain
processing in patients with FM41. This technique reveals
sensitivity to input from unmyelinated (C) afferents and
indicates the status of NMDA receptor systems, which
are implicated in a variety of chronic pain conditions.
Using a series of repetitive heat stimuli, we assessed
temporal summation of second pain in both healthy con-
trols and FM subjects41. Although windup pain was
evoked in both controls and patients, the perceived mag-
nitude of the sensory response to the first stimulus with-
in a series was greater for patients versus controls, as was
the degree of temporal summation within a series (Figure
2). Following the last stimulus in a series, painful windup
after-sensations rated at 15 and 30 seconds after the last
stimulus also were greater in magnitude and lasted longer
in FM subjects compared to controls. These results indi-
cate both augmentation and slower decay of nociceptive
input in FM patients and provide convincing evidence for
the presence of central sensitization.
The more prolonged after-sensations during windup
decay, however, may have been simply related to the fact
that greater windup occurred in FM patients. In order to
specifically test whether after-sensations are more intense
and take longer to decay in FM versus controls, we
adjusted the stimulus temperature in a manner that
evoked similar windup pain in both groups, as shown in
Figure 3. Despite similar temporal summation in both
groups, after-sensations were more intense and took
more than twice as long to decay in FM compared to
control subjects. Thus, the presence of enhanced windup
tion wherein nociceptive neurons of the dorsal horn
become hyperresponsive to nociceptive and sometimes
even non-nociceptive somatic stimulation25,26. Central
sensitization, in turn, is characterized by hyperalgesia
and allodynia. It is associated with enlarged receptive
fields and is often thought to occur as a consequence of
slow temporal summation of dorsal horn neurons to
repeated impulses from primary nociceptive neurons.
Since this repetitive impulse input can be elicited by
experimental laboratory stimuli, central sensitization and
windup can be studied in both normal pain-free subjects
and in patients with pain conditions such as FM.
NEUROPHYSIOLOGICAL ABNORMALITIES IN FM
Before we discuss the specific abnormalities of windup in
patients with FM, it would be useful to consider some
general sensory abnormalities and physiological charac-
teristics of these patients.
As described by Mease elsewhere in these proceedings,
FM is a chronic pain syndrome characterized by general-
ized pain, tender points (TP), disturbed sleep, and pro-
nounced fatigue. Pain in FM is consistently felt in the
musculature and may be related to sensitization of CNS
pain pathways. The pathogenesis of FM is unknown,
although abnormal concentration of CNS neuropeptides
and alterations of hypothalamic-pituitary-adrenal axis
have been described27-30. There is a large body of evi-
dence for a generalized lowering of pressure pain thresh-
olds in FM patients31-35. This mechanical allodynia of
FM patients, however, is not limited to TP, but appears to
be widespread35. In addition, almost all studies of FM
patients showed abnormalities of pain sensitivity while
using different methods of psychophysical testing. Most
investigations have utilized thermal (heat and cold),
mechanical, chemical, or electrical stimuli (single or
repetitive) to the skin or muscles.
The most frequently described sensory abnormality in
FM is the presence of TP. Eighteen areas have been
defined as tender points by the American College of
Rheumatology36. In addition to chronic widespread pain,
the presence of decreased mechanical pain thresholds
(tenderness) is required in at least 11 out of 18 TP for the
diagnosis of FM. Abnormal tenderness, however, does
not seem to be restricted to TP sites in FM but this
abnormality is most frequently generalized33,35. Most TP
are located at tendon insertion areas and have shown few
detectable tissue abnormalities. Analysis of algesic sub-
stances at TP sites by microdialysis showed no difference
between FM patients and healthy controls37 and magnet-
ic resonance imaging of TP was also unable to detect any
specific abnormalities38. Although there is evidence for
local vasoconstriction of TP areas in FM39, these find-
ings may mostly reflect physical deconditioning40.
Figure 2. Windup of second pain in 10 female patients with FM and
healthy controls, using repetitive heat stimuli of 52°C to the hand.
Contact time of each stimulus was 0.7 s and ISI was 2 s. The rating of
only the first and last stimulus (n = 20) of each series is shown. Pain
intensity of test stimuli was rated on a verbal rating scale of 0–100 (see
definition, legend to Figure 1). From Vierck, et al. J Neurophysiol
1997;78:992-100217.
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and prolonged stimulus-evoked after-sensations may be
functionally important for the initiation and mainte-
nance of persistent pain conditions such as FM.
Enhanced magnitudes of windup of second pain and
enhanced after-sensations are unlikely to be related to a
response bias because these characteristics are highly spe-
cific. For example, there is no reason why patients with
FM would expect enhanced after-sensations when their
magnitude of windup of second pain is adjusted to match
that of healthy subjects. Further, FM patients do not
complain of ongoing heat pain, but rather pain from
deep tissues. Thus, it is possible that central sensitization
is evoked and maintained by impulses in deep tissues and
thereby produces a central sensitized state during which
central neurons are hyperresponsive to multiple sensory
inputs, including cutaneous heat. There is recent evidence
for this kind of peripheral and central interaction in irri-
table bowel syndrome42. Given these considerations,
windup of heat-induced second pain may be a valuable
diagnostic test in FM patients.
WINDUP MEASURES PREDICT CLINICAL PAIN
INTENSITY IN FM PATIENTS
If windup and central sensitization are important mech-
anisms for FM pain, one should expect robust associa-
tions between windup, windup decay, and clinical pain
intensity. In order to test the role of central pain mecha-
nisms such as windup and windup decay for clinical pain
we evaluated their usefulness as predictors of pain inten-
sity of patients with FM. We found that thermal windup
ratings correlated well with clinical pain intensity
(Pearson’s r = 0.529), thus emphasizing the important
role of these pain mechanisms for FM. In addition, a sta-
tistical prediction model that included TP count, pain
related negative affect, and windup ratings accounted for
50% of the variance in FM clinical pain intensity43.
Importantly, each of these 3 factors was shown to statis-
tically account for unique amounts of variance in clinical
pain intensity. Windup after-sensation, however, was the
strongest predictor of clinical pain intensity, accounting
for most of the detectable variance (27%).
ABNORMAL MUSCLE WINDUP IN PATIENTS
WITH FM 
We have proposed that impulse input from deep tissues,
particularly muscles, reflects the peripheral source that
evokes and maintains central sensitization in FM23. This
proposal predicts that repeated stimulation of muscle
nociceptors would induce windup and central sensitiza-
tion in FM patients. Accordingly, we conducted a study
in which force-controlled mechanical stimulation was
applied to the flexor digitorum muscle of the forearm in
a series of brief contacts (15 stimuli, each of 1 second
duration, at 3 or 5 second interstimulus intervals)23.
These trains of stimuli were applied to both healthy con-
trols and FM patients, as shown in Figure 4. Similar to
cutaneous heat stimuli, FM patients demonstrated much
more pronounced windup as well as more intense and
Figure 3. The decay of pain after windup is slower for FM patients compared to healthy
control subjects (HC) even when the stimulus temperature is adjusted for the 2 groups to
produce the same magnitude of windup. After-sensations at 15 and 30 seconds after last
stimulus are painful for FM but not control subjects. The shaded area represents pain
threshold of the verbal pain rating scale (0-100) used for this study. Based on data from
Staud, et al43. Pain 2003;105:215-22.
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slower declining after-sensations compared to control
subjects.
EFFECT OF EXERCISE ON FM PAIN
The explanation we have proposed thus far is that evoked
or ongoing impulse input from deep tissues induces and
maintains central sensitization in patients with FM. This
explanation raises the question of how this peripheral
input is generated. One obvious possibility is that of exer-
cise of muscles associated with abnormal sensitivity
(mechanical allodynia). Exercise has been shown to acti-
vate endogenous opioid and adrenergic systems, but
attenuation of experimental pain by exercise has not been
demonstrated consistently. We therefore assessed the
antinociceptive effects of exercise on windup, a psy-
chophysical method that is especially sensitive to opioid
modulation, in both healthy controls and FM patients44.
In addition, we determined the effects of exercise on
windup after-sensations evoked by repeated thermal
stimuli as described above. Temporal summation of late
pain sensations was substantially attenuated by strenuous
exercise in controls, but enhanced in individuals diag-
nosed with FM, an effect opposite to that obtained from
age/sex matched control subjects. This study indirectly
implicates a role of muscle nociceptors in FM pain and
also suggests that analgesic effects of exercise may be
lacking in FM patients.
Another line of evidence suggests that powerful
antinociceptive mechanisms become activated during
muscle contraction in healthy control subjects45.
Specifically, during isometric muscle contraction of con-
trol subjects, the mechanical pain threshold increases
over the contracted muscles as well as over distal muscle
areas46. In FM patients, however, the pain threshold
decreased over all areas, more pronounced proximal to
the muscle contraction compared to distal47. This exer-
cise related hyperalgesia may be the result of either sensi-
tization of mechanoreceptors in FM or dysfunction of
afferent pain inhibition activated by muscle contraction.
These findings may explain some of the increased pain
during exertion that is reported by FM patients.
ROLE OF MUSCLES FOR CLINICAL PAIN IN FM
The predominant symptom in FM is muscle pain and
stiffness, consistent with our explanation thus far. In fact,
many studies have focused on muscle tissue abnormalities
in FM48,49. Light and electron microscopic evaluations
identified moth-eaten and ragged-red fibers, indicating
uneven and proliferating mitochondria. This finding sug-
gested hypoperfusion of painful muscle tissues and has
led to examinations of muscle microcirculation. Oxygen
multipoint electrodes in trapezius muscles identified
abnormal tissue oxygen pressures in FM patients.
Because microcirculation of muscle tissues is controlled
by locally produced metabolites, humoral factors, and the
sympathetic nervous system, several investigations
focused on these possible mechanisms48,50,51. Sympathetic
ganglion blockade reversed the abnormal muscle find-
ings. In addition, the amount of SP, a neurotransmitter
stored within the afferent nociceptive fibers, was found to
be increased in the trapezius muscles of FM patients
compared to healthy controls52.
Skeletal muscles have different fiber types, including
type I, type IIA, and type IIB. Type I muscle fibers are
Figure 4. Pain ratings during a series of 15 repetitive muscle taps at ISI of 3 and 5 s, aver-
aged across all series presented to controls (HC) and patients with FM. The shaded area
identifies sensation levels below pain threshold (a rating of 20). Based on data from Staud,
et al23. Pain 2003;102:87-95.
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associated with static muscle tone and posture. They are
slow-twitch, fatigue resistant myocytes that contain high
numbers of mitochondria for oxidative phosphorylation.
Type II fibers are fast-twitch fibers and have high con-
traction force over short periods. They fatigue easily, are
rich in glycogen, and use anaerobic glycolysis for energy
metabolism. Type I muscle fibers can transform into type
II fibers depending on demand placed on individual mus-
cles. Therefore, inactivity and pain can be responsible in
type II fiber loss/transformation.
Ionotropic and metabotropic nociceptors are found on
peripheral unmyelinated sensory afferents in the skin and
muscle53. These polymodal muscle nociceptors are locat-
ed along blood vessels, except capillaries54, and comprise
free nerve endings supplied by group III (thin myelinated)
and group IV (nonmyelinated) afferents, with conduction
velocities of less than 30 m/s. The nerve endings have
receptors for algesic substances like bradykinin, sero-
tonin, glutamate, and prostaglandin E2
55,56, which con-
tribute to the sensitization of muscle nociceptors57,58.
This sensitization process by endogenous substances that
are likely to be released during trauma or inflammatory
injury is probably the best established peripheral mecha-
nism for muscle tenderness and hyperalgesia. Although
information about responses of muscle nociceptors is
largely based on animal studies59,60, similar findings have
also been reported from human studies61,62.
CONCLUSION
Accumulating evidence suggests that FM pain is main-
tained by a combination of tonic impulse input from
deep tissues, such as muscle and joints, in combination
with central sensitization mechanisms. This nociceptive
input may originate in peripheral tissues (trauma and
infection) and result in hyperalgesia/allodynia and/or
central sensitization. Such alterations of relevant pain
mechanisms may lead to longterm neuroplastic changes
that exceed the antinociceptive capabilities of affected
individuals, resulting in ever-increasing pain sensitivity
and dysfunction. Future research needs to address the
important role of abnormal nociception and/or antinoci-
ception for chronic pain in FM.
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